leadf
logo-loader
viewGreen Organic Dutchman Holdings Ltd.

The Green Organic Dutchman taps two new board members

TGOD has appointed internist and cannabinoid expert Dr. Caroline MacCallum and Jacques Dessureault, a pharmaceutical executive, to its board

medical cannabis and pill bottle
MacCallum's recent publication - Practical Consideration for Medical Cannabis Administration and Dosing - offers guidance on medical cannabis dosing

The Green Organic Dutchman Holdings Ltd (TSE:TGOD) (OTCMKTS:TGODF) has appointed Dr. Caroline MacCallum and Jacques Dessureault to its board.

An expert in cannabinoid-based medicine, Dr MacCallum is an internist and cannabinoid clinician as well as a researcher and instructor in the department of medicine at the University of British Columbia. She is also an associate member of the University of British Columbia’s palliative care department, as well as the medical director at Greenleaf Medical Clinic, where she has developed cannabinoid treatment plans for more than 3,000 patients across Canada.

READ: The Green Organic Dutchman continues blazing a trail into international cannabis markets

Her recent publication, Practical Consideration for Medical Cannabis Administration and Dosing, offers guidance on medical cannabis dosing.

“Dr MacCallum’s vast experience in cannabinoid research will be invaluable to TGOD,” said Brian Athaide, CEO of The Green Organic Dutchman in a statement.

“She has been recognized by her peers in the medical industry as an expert in medical cannabis with a focus on dosing, which will be critical as we prepare to launch a suite of multi-dose products under the recently announced responsible Regulation of Edible Cannabis Products in Canada,” Athaide added.

Dessureault, meanwhile, hails from the pharmaceutical industry. He has worked as a global marketing division head for Novartis and as the president and general manager of Valeant Pharmaceuticals International Inc (NYSE:VRX) as well as a vice-president at Bristol Myers-Squibb. During Dessureault's time at Valeant, he led all Canadian commercial units, including research and development and international manufacturing and technical operations

"As we advance the research and development arms of our Company, including our beverage science and research division, Jacques' experience will be critical to launching new novel and innovative product lines," said Athaide.

The Green Organic Dutchman is a research and development company licensed by Canadian regulators to cultivate medical cannabis. It has cultivation facilities in Ontario, Quebec and Jamaica.

It has organic cannabis operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America as well as the recreational cannabis market in Canada. The company’s products are tested in labs to ensure their safety and consistency.

Shares in The Green Organic Dutchman closed down 1.9% to finish at C$2.54 on Monday.

Contact Ellen Kelleher at ellen@proactiveinvestors.com

 

 

Quick facts: Green Organic Dutchman Holdings Ltd.

Price: 0.35 CAD

TSX:TGOD
Market: TSX
Market Cap: $169.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Green Organic Dutchman Holdings Ltd. named herein, including the promotion by the Company of Green Organic Dutchman Holdings Ltd. in any...

FOR OUR FULL DISCLAIMER CLICK HERE

Buds & Duds: Ontario's cannabis retail expansion plan gives cannabis stocks...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was 1.4% higher at 116.7 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF jumped 2.4% at C$9.55, while the OTCQX Cannabis index gained 0.6% to 434 points. Buds today are The Green...

on 12/13/2019

2 min read